Arpinati, Ludovica
Shaul, Merav E.
Kaisar-Iluz, Naomi
Mali, Shira
Mahroum, Sojod
Fridlender, Zvi G. http://orcid.org/0000-0002-6122-1988
Funding for this research was provided by:
DKFZ-MOST Cooperation in Cancer Research (2656)
Israel Lung Association (N/A)
Naor Sasson Fund (N/A)
Article History
Received: 15 August 2019
Accepted: 31 December 2019
First Online: 25 January 2020
Compliance with ethical standards
:
: The authors declare that they have no conflict of interest.
: All procedures involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the Hadassah Medical Center Institutional Helsinki Review Board, approval number: 0615-16-HMO (Nov 4th 2016). All procedures involving animals were in accordance with the ethical standards of the Animal Care and Research Committee of the Hebrew University School of Medicine; study approval number 14697-5 (August 8th 2017).
: Written informed consent was obtained from all participants before blood samples were taken. Patients and heatly volunteers consented to the use of blood sample for research purposes and for publication.
: C57BL/6 mice and Balb/C mice, 6–8 week of age, 20–25 g weight, were purchased from Harlan Laboratories (Jerusalem, Israel) and were housed under specific pathogen-free (SPF) conditions at the Hebrew University School of Medicine Animal Resource Center.
: Murine LLC cell line was purchased from the American Type Culture Collection (ATCC, Manassas, VA). AB12, a murine malignant mesothelioma cell line, derived from an asbestos-induced tumor in a Balb/C mouse, was kindly provided by Prof. Steven Albelda, University of Pennsylvania, PA, USA. The cell lines were expanded and cryopreserved according to ATCC guidelines, and regularly checked for mycobacteria.